110 results on '"Leppä, Sirpa"'
Search Results
2. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
- Author
-
Dreyling, Martin, Doorduijn, Jeanette, Giné, Eva, Jerkeman, Mats, Walewski, Jan, Hutchings, Martin, Mey, Ulrich, Riise, Jon, Trneny, Marek, Vergote, Vibeke, Shpilberg, Ofer, Gomes da Silva, Maria, Leppä, Sirpa, Jiang, Linmiao, Stilgenbauer, Stephan, Kerkhoff, Andrea, Jachimowicz, Ron D, Celli, Melania, Hess, Georg, Arcaini, Luca, Visco, Carlo, van Meerten, Tom, Wirths, Stefan, Zinzani, Pier Luigi, Novak, Urban, Herhaus, Peter, Benedetti, Fabio, Sonnevi, Kristina, Hanoun, Christine, Hänel, Matthias, Dierlamm, Judith, Pott, Christiane, Klapper, Wolfram, Gözel, Döndü, Schmidt, Christian, Unterhalt, Michael, Ladetto, Marco, and Hoster, Eva
- Abstract
Adding ibrutinib to standard immunochemotherapy might improve outcomes and challenge autologous stem-cell transplantation (ASCT) in younger (aged 65 years or younger) mantle cell lymphoma patients. This trial aimed to investigate whether the addition of ibrutinib results in a superior clinical outcome compared with the pre-trial immunochemotherapy standard with ASCT or an ibrutinib-containing treatment without ASCT. We also investigated whether standard treatment with ASCT is superior to a treatment adding ibrutinib but without ASCT.
- Published
- 2024
- Full Text
- View/download PDF
3. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial
- Author
-
Jerkeman, Mats, Kolstad, Arne, Hutchings, Martin, Pasanen, Annika, Meriranta, Leo, Niemann, Carsten Utoft, Kragh Jørgensen, Rasmus Rask, El-Galaly, Tarec Christoffer, Riise, Jon, Leppä, Sirpa, Christensen, Jacob Haaber, Sonnevi, Kristina, Pedersen, Lone Bredo, Wader, Karin Fahl, and Glimelius, Ingrid
- Abstract
•Venetoclax-R2 is an active regimen in R/R MCL, showing an ORR of 63%.•Forty-eight percent of patients discontinued treatment of venetoclax-R2 because of molecular remission.
- Published
- 2024
- Full Text
- View/download PDF
4. Deep and Durable Responses with Epcoritamab SC Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Data from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort
- Author
-
Linton, Kim M, Jurczak, Wojciech, Lugtenburg, Pieternella J., Gyan, Emmanuel, Sureda, Anna, Christensen, Jacob Haaber, Hess, Brian, Tilly, Herve, Cordoba, Raul, Lewis, David John, Okada, Craig, Hutchings, Martin, Clausen, Michael Roost, Vitolo, Umberto, Cochrane, Tara, Leppä, Sirpa, Chamuleau, Martine E.D., Conlon, Rebekah, Favaro, Elena, Favaro, Diana, Altıntaş, Işıl, Liu, Yan, and Thieblemont, Catherine
- Abstract
An unmet need exists for effective, well-tolerated, and convenient treatment (tx) options in patients (pts) with high-risk relapsed/refractory (R/R) follicular lymphoma (FL), including double refractory pts (refractory to anti-CD20 tx and an alkylating agent) and pts with disease progression within 2 y of first-line (1L) immunochemotherapy (POD24). Epcoritamab, a subcutaneous (SC) CD3xCD20 bispecific antibody, is approved in the US for adults with R/R diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after ≥2 lines of systemic tx. We present initial results from the FL dose-expansion cohort of the EPCORE™ NHL-1 trial (NCT03625037; phase 1/2).
- Published
- 2024
- Full Text
- View/download PDF
5. Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas
- Author
-
Arffman, Maare, Meriranta, Leo, Autio, Matias, Holte, Harald, Jørgensen, Judit, Brown, Peter, Jyrkkiö, Sirkku, Jerkeman, Mats, Drott, Kristina, Fluge, Øystein, Björkholm, Magnus, Karjalainen-Lindsberg, Marja-Liisa, Beiske, Klaus, Pedersen, Mette Ølgod, Leivonen, Suvi-Katri, and Leppä, Sirpa
- Abstract
Biological heterogeneity of large B cell lymphomas (LBCLs) is poorly captured by current prognostic tools, hampering optimal treatment decisions.
- Published
- 2024
- Full Text
- View/download PDF
6. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
- Author
-
Meriranta, Leo, Alkodsi, Amjad, Pasanen, Annika, Lepistö, Maija, Mapar, Parisa, Blaker, Yngvild Nuvin, Jørgensen, Judit, Karjalainen-Lindsberg, Marja-Liisa, Fiskvik, Idun, Mikalsen, Lars Tore G., Autio, Matias, Björkholm, Magnus, Jerkeman, Mats, Fluge, Øystein, Brown, Peter, Jyrkkiö, Sirkku, Holte, Harald, Pitkänen, Esa, Ellonen, Pekka, and Leppä, Sirpa
- Abstract
Inadequate molecular and clinical stratification of the patients with high-risk diffuse large B-cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalized therapeutic options. We studied the translational significance of liquid biopsy in a uniformly treated trial cohort. Pretreatment circulating tumor DNA (ctDNA) revealed hidden clinical and biological heterogeneity, and high ctDNA burden determined increased risk of relapse and death independently of conventional risk factors. Genomic dissection of pretreatment ctDNA revealed translationally relevant phenotypic, molecular, and prognostic information that extended beyond diagnostic tissue biopsies. During therapy, chemorefractory lymphomas exhibited diverging ctDNA kinetics, whereas end-of-therapy negativity for minimal residual disease (MRD) characterized cured patients and resolved clinical enigmas, including false residual PET positivity. Furthermore, we discovered fragmentation disparities in the cell-free DNA that characterize lymphoma-derived ctDNA and, as a proof-of-concept for their clinical application, used machine learning to show that end-of-therapy fragmentation patterns predict outcome. Altogether, we have discovered novel molecular determinants in the liquid biopsy that can noninvasively guide treatment decisions.
- Published
- 2022
- Full Text
- View/download PDF
7. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients
- Author
-
Karihtala, Kristiina, Leivonen, Suvi-Katri, Karjalainen-Lindsberg, Marja-Liisa, Chan, Fong Chun, Steidl, Christian, Pellinen, Teijo, and Leppä, Sirpa
- Abstract
Emerging evidence indicates a major impact for the tumor microenvironment (TME) and immune escape in the pathogenesis and clinical course of classical Hodgkin lymphoma (cHL). We used gene expression profiling (n = 88), CIBERSORT, and multiplex immunohistochemistry (n = 131) to characterize the immunoprofile of cHL TME and correlated the findings with survival. Gene expression analysis divided tumors into subgroups with T cell-inflamed and -noninflamed TME. Several macrophage-related genes were upregulated in samples with the non–T cell-inflamed TME, and based on the immune cell proportions, the samples clustered according to the content of T cells and macrophages. A cluster with high proportions of checkpoint protein (programmed cell death protein 1, PD-1 ligands, indoleamine 2,3 dioxygenase 1, lymphocyte-activation gene 3, and T-cell immunoglobulin and mucin domain containing protein 3) positive immune cells translated to unfavorable overall survival (OS) (5-year OS 76% vs 96%; P = .010) and remained an independent prognostic factor for OS in multivariable analysis (HR, 4.34; 95% CI, 1.05-17.91; P = .043). cHL samples with high proportions of checkpoint proteins overexpressed genes coding for cytolytic factors, proposing paradoxically that they were immunologically active. This checkpoint molecule gene signature translated to inferior survival in a validation cohort of 290 diagnostic cHL samples (P < .001) and in an expansion cohort of 84 cHL relapse samples (P = .048). Our findings demonstrate the impact of T cell- and macrophage-mediated checkpoint system on the survival of patients with cHL.
- Published
- 2022
- Full Text
- View/download PDF
8. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients
- Author
-
Karihtala, Kristiina, Leivonen, Suvi-Katri, Karjalainen-Lindsberg, Marja-Liisa, Chan, Fong Chun, Steidl, Christian, Pellinen, Teijo, and Leppä, Sirpa
- Abstract
Emerging evidence indicates a major impact for the tumor microenvironment (TME) and immune escape in the pathogenesis and clinical course of classical Hodgkin lymphoma (cHL). We used gene expression profiling (n = 88), CIBERSORT, and multiplex immunohistochemistry (n = 131) to characterize the immunoprofile of cHL TME and correlated the findings with survival. Gene expression analysis divided tumors into subgroups with T cell-inflamed and -noninflamed TME. Several macrophage-related genes were upregulated in samples with the non–T cell-inflamed TME, and based on the immune cell proportions, the samples clustered according to the content of T cells and macrophages. A cluster with high proportions of checkpoint protein (programmed cell death protein 1, PD-1 ligands, indoleamine 2,3 dioxygenase 1, lymphocyte-activation gene 3, and T-cell immunoglobulin and mucin domain containing protein 3) positive immune cells translated to unfavorable overall survival (OS) (5-year OS 76% vs 96%; P= .010) and remained an independent prognostic factor for OS in multivariable analysis (HR, 4.34; 95% CI, 1.05-17.91; P= .043). cHL samples with high proportions of checkpoint proteins overexpressed genes coding for cytolytic factors, proposing paradoxically that they were immunologically active. This checkpoint molecule gene signature translated to inferior survival in a validation cohort of 290 diagnostic cHL samples (P< .001) and in an expansion cohort of 84 cHL relapse samples (P= .048). Our findings demonstrate the impact of T cell- and macrophage-mediated checkpoint system on the survival of patients with cHL.
- Published
- 2022
- Full Text
- View/download PDF
9. Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
- Author
-
Falchi, Lorenzo, Abrisqueta, Pau, Nijland, Marcel, Leppä, Sirpa, Hutchings, Martin, Holte, Harald, Merryman, Reid W, Lugtenburg, Pieternella, de Vos, Sven, Cheah, Chan Y., Christensen, Jacob Haaber, Arcaini, Luca, Drott, Kristina, Hellström, Mats, Leslie, Lori A., Vitolo, Umberto, Rana, Ali, Abbas, Aqeel, Wang, Liwei, Dinh, Minh, and Belada, David
- Published
- 2022
- Full Text
- View/download PDF
10. Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
- Author
-
Falchi, Lorenzo, Abrisqueta, Pau, Nijland, Marcel, Leppä, Sirpa, Hutchings, Martin, Holte, Harald, Merryman, Reid W, Lugtenburg, Pieternella, de Vos, Sven, Cheah, Chan Y., Christensen, Jacob Haaber, Arcaini, Luca, Drott, Kristina, Hellström, Mats, Leslie, Lori A., Vitolo, Umberto, Rana, Ali, Abbas, Aqeel, Wang, Liwei, Dinh, Minh, and Belada, David
- Published
- 2022
- Full Text
- View/download PDF
11. Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma
- Author
-
Meriranta, Leo, Pasanen, Annika, Alkodsi, Amjad, Haukka, Jari, Karjalainen-Lindsberg, Marja-Liisa, and Leppä, Sirpa
- Abstract
Concomitant deregulation of MYCand BCL2comprises clinically significant, yet poorly characterized biological high-risk feature in diffuse large B-cell lymphoma (DLBCL). To interrogate these lymphomas, we analyzed translocations and protein expression of BCL2, BCL6, and MYC; correlated the findings with comprehensive mutational, transcriptomic, and clinical data in 181 patients with primary DLBCL; and validated the key findings in independent data sets. Structural variations of BCL2were subtype-specific and specifically increased BCL2 expression. Molecular dissection of MYCderegulation revealed associations with other lymphoma drivers, including loss of TP53, and distinctive gene expression profiles. Double protein expression (DPE) arose from heterogeneous molecular backgrounds that exhibited subtype-dependent patterns. In the germinal center B-cell (GCB) DLBCL, concurrent alterations of MYCand BCL2loci gave rise to the majority of DPE DLBCLs, whereas among the activated B-cell (ABC) DLBCLs, concurrent alterations were infrequent. Clinically, DPE DLBCL defined a prognostic entity, which was independent of the International Prognostic Index (IPI) and cell of origin, and together with the loss of TP53had a synergistic dismal impact on survival. In the DPE DLBCL, the loss of TP53was associated with a chemorefractory disease, whereas among the other DLBCLs, no correlation with survival was seen. Importantly, BCL6translocations identified non-GCB lymphomas with favorable BN2/C1-like survival independent of IPI and concurrent DPE status. Taken together, our findings define molecular characteristics of the DPE in DLBCL, and recognize clinically feasible predictors of outcome. Given the emerging taxonomical significance of BCL2, BCL6, MYC, and TP53, our findings provide further depth and validation to the genomic classification of DLBCL.
- Published
- 2020
- Full Text
- View/download PDF
12. Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
- Author
-
Wise, Jillian F., Nakken, Sigve, Steen, Chloé B., Vodák, Daniel, Trøen, Gunhild, Johannessen, Bjarne, Lingjærde, Ole Christian, Hilden, Vera, Blaker, Yngvild Nuvin, Bai, Baoyan, Aasheim, Lars Birger, Pasanen, Annika, Lorenz, Susanne, Sveen, Anita, Lothe, Ragnhild A., Myklebost, Ola, Leppä, Sirpa, Meza-Zepeda, Leonardo A., Beiske, Klaus, Lawrence, Michael S., Hovig, Eivind, Myklebust, June Helen, Smeland, Erlend B., and Holte, Harald
- Published
- 2020
- Full Text
- View/download PDF
13. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
- Author
-
Leppä, Sirpa, Jørgensen, Judit, Tierens, Anne, Meriranta, Leo, Østlie, Ingunn, de Nully Brown, Peter, Fagerli, Unn-Merete, Larsen, Thomas Stauffer, Mannisto, Susanna, Munksgaard, Lars, Maisenhölder, Martin, Vasala, Kaija, Meyer, Peter, Jerkeman, Mats, Björkholm, Magnus, Fluge, Øystein, Jyrkkiö, Sirkku, Liestøl, Knut, Ralfkiaer, Elisabeth, Spetalen, Signe, Beiske, Klaus, Karjalainen-Lindsberg, Marja-Liisa, and Holte, Harald
- Abstract
Survival of patients with high-risk diffuse large B-cell lymphoma (DLBCL) is suboptimal, and the risk of central nervous system (CNS) progression is relatively high. We conducted a phase 2 trial in 139 patients aged 18 to 64 years who had primary DLBCL with an age-adjusted International Prognostic Index (aaIPI) score of 2 to 3 or site-specific risk factors for CNS recurrence. The goal was to assess whether a dose-dense immunochemotherapy with early systemic CNS prophylaxis improves the outcome and reduces the incidence of CNS events. Treatment consisted of 2 courses of high-dose methotrexate in combination with biweekly rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-14), followed by 4 courses of R-CHOP-14 with etoposide (R-CHOEP) and 1 course of high-dose cytarabine with R. In addition, liposomal cytarabine was administered intrathecally at courses 1, 3, and 5. Coprimary endpoints were failure-free survival and CNS progression rates. Thirty-six (26%) patients experienced treatment failure. Progression occurred in 23 (16%) patients, including three (2.2%) CNS events. At 5 years of median follow-up, failure-free survival, overall survival, and CNS progression rates were 74%, 83%, and 2.3%, respectively. Treatment reduced the risk of progression compared with our previous trial, in which systemic CNS prophylaxis was given after 6 courses of biweekly R-CHOEP (hazard ratio, 0.49; 95% CI, 0.31-0.77; P = .002) and overcame the adverse impact of an aaIPI score of 3 on survival. In addition, outcome of the patients with BCL2/MYC double-hit lymphomas was comparable to the patients without the rearrangements. The results are encouraging, with a low toxic death rate, low number of CNS events, and favorable survival rates. This trial was registered at www.clinicaltrials.gov as #NCT01325194.
- Published
- 2020
- Full Text
- View/download PDF
14. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
- Author
-
Leppä, Sirpa, Jørgensen, Judit, Tierens, Anne, Meriranta, Leo, Østlie, Ingunn, de Nully Brown, Peter, Fagerli, Unn-Merete, Larsen, Thomas Stauffer, Mannisto, Susanna, Munksgaard, Lars, Maisenhölder, Martin, Vasala, Kaija, Meyer, Peter, Jerkeman, Mats, Björkholm, Magnus, Fluge, Øystein, Jyrkkiö, Sirkku, Liestøl, Knut, Ralfkiaer, Elisabeth, Spetalen, Signe, Beiske, Klaus, Karjalainen-Lindsberg, Marja-Liisa, and Holte, Harald
- Abstract
Survival of patients with high-risk diffuse large B-cell lymphoma (DLBCL) is suboptimal, and the risk of central nervous system (CNS) progression is relatively high. We conducted a phase 2 trial in 139 patients aged 18 to 64 years who had primary DLBCL with an age-adjusted International Prognostic Index (aaIPI) score of 2 to 3 or site-specific risk factors for CNS recurrence. The goal was to assess whether a dose-dense immunochemotherapy with early systemic CNS prophylaxis improves the outcome and reduces the incidence of CNS events. Treatment consisted of 2 courses of high-dose methotrexate in combination with biweekly rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-14), followed by 4 courses of R-CHOP-14 with etoposide (R-CHOEP) and 1 course of high-dose cytarabine with R. In addition, liposomal cytarabine was administered intrathecally at courses 1, 3, and 5. Coprimary endpoints were failure-free survival and CNS progression rates. Thirty-six (26%) patients experienced treatment failure. Progression occurred in 23 (16%) patients, including three (2.2%) CNS events. At 5 years of median follow-up, failure-free survival, overall survival, and CNS progression rates were 74%, 83%, and 2.3%, respectively. Treatment reduced the risk of progression compared with our previous trial, in which systemic CNS prophylaxis was given after 6 courses of biweekly R-CHOEP (hazard ratio, 0.49; 95% CI, 0.31-0.77; P= .002) and overcame the adverse impact of an aaIPI score of 3 on survival. In addition, outcome of the patients with BCL2/MYCdouble-hit lymphomas was comparable to the patients without the rearrangements. The results are encouraging, with a low toxic death rate, low number of CNS events, and favorable survival rates. This trial was registered at www.clinicaltrials.govas #NCT01325194.
- Published
- 2020
- Full Text
- View/download PDF
15. Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
- Author
-
Wise, Jillian F., Nakken, Sigve, Steen, Chloé B., Vodák, Daniel, Trøen, Gunhild, Johannessen, Bjarne, Lingjærde, Ole Christian, Hilden, Vera, Blaker, Yngvild Nuvin, Bai, Baoyan, Aasheim, Lars Birger, Pasanen, Annika, Lorenz, Susanne, Sveen, Anita, Lothe, Ragnhild A., Myklebost, Ola, Leppä, Sirpa, Meza-Zepeda, Leonardo A., Beiske, Klaus, Lawrence, Michael S., Hovig, Eivind, Myklebust, June Helen, Smeland, Erlend B., and Holte, Harald
- Abstract
•Diagnostic and relapse diffuse large B-cell lymphoma (DLBCL) biopsies reveal increased mutational burden/loss of heterozygosity in HLA-A.•Serially sampled tumor biopsies provide insight into therapeutic targets and evolutionary divergence in relapsed/refractory DLBCL.
- Published
- 2020
- Full Text
- View/download PDF
16. Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes
- Author
-
Alkodsi, Amjad, Cervera, Alejandra, Zhang, Kaiyang, Louhimo, Riku, Meriranta, Leo, Pasanen, Annika, Leivonen, Suvi-Katri, Holte, Harald, Leppä, Sirpa, Lehtonen, Rainer, and Hautaniemi, Sampsa
- Abstract
Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease whose personalized clinical management requires robust molecular stratification. Here, we show that somatic hypermutation (SHM) patterns constitute a marker for DLBCL molecular classification. The activity of SHM mutational processes delineated the cell of origin (COO) in DLBCL. Expression of the herein identified 36 SHM target genes stratified DLBCL into four novel SHM subtypes. In a meta-analysis of patients with DLBCL treated with immunochemotherapy, the SHM subtypes were significantly associated with overall survival (1642 patients) and progression-free survival (795 patients). Multivariate analysis of survival indicated that the prognostic impact of the SHM subtypes is independent from the COO classification and the International Prognostic Index. Furthermore, the SHM subtypes had a distinct clinical outcome within each of the COO subtypes, and strikingly, even within unclassified DLBCL. The genetic landscape of the four SHM subtypes indicated unique associations with driver alterations and oncogenic signaling in DLBCL, which suggests a possibility for therapeutic exploitation. These findings provide a biologically driven classification system in DLBCL with potential clinical applications.
- Published
- 2019
- Full Text
- View/download PDF
17. Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume
- Author
-
Hutchings, Martin, Carlo-Stella, Carmelo, Morschhauser, Franck, Falchi, Lorenzo, Bachy, Emmanuel, Cartron, Guillaume, Khan, Cyrus, Tani, Monica, Martinez-Lopez, Joaquin, Bartlett, Nancy L., Salar, Antonio, Brody, Joshua, Leppä, Sirpa, Baumlin, Pauline, Mulvihill, Estefania, Relf, James, Xie, Yuying, Kaufman, Derrick, Lundberg, Linda, and Dickinson, Michael
- Abstract
Background:Glofitamab is a CD20xCD3 bispecific antibody with a 2:1 (CD20:CD3) format that engages and redirects T cells to eliminate B cells. In a pivotal Phase II study (NCT03075696), fixed-duration glofitamab monotherapy induced high complete response (CR) rates and had a manageable safety profile in patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL; Dickinson et al. N Engl J Med 2022). Here, we present an extended follow up, as well as subgroup analyses in patients with prior chimeric antigen receptor (CAR) T-cell therapy and by baseline total metabolic tumor volume (TMTV).
- Published
- 2023
- Full Text
- View/download PDF
18. Unraveling the Role and Spatial Architecture of Cancer-Associated Fibroblasts in Classical Hodgkin Lymphoma
- Author
-
Leivonen, Suvi-Katri, Karihtala, Kristiina, Karjalainen-Lindsberg, Marja-Liisa, Pellinen, Teijo, and Leppä, Sirpa
- Abstract
Introduction: Cancer-associated fibroblasts (CAFs) constitute an important stromal component of the tumor microenvironment (TME). They are a heterogeneous population of cells, which can modulate the immune system and have both pro-tumorigenic and anti-tumorigenic effects in a context-dependent manner. In solid tumors, the impact of CAFs in shaping the TME is well recognized, although challenges, including lack of specific CAF markers, still exist. In classical Hodgkin lymphoma (cHL), the role of CAFs has remained largely undefined. Here, we aimed to characterize distinct CAF subsets as well as their interactions with other TME cells and associate the findings with clinical characteristics and outcome of patients with previously untreated cHL.
- Published
- 2023
- Full Text
- View/download PDF
19. Joint Analyses of Serum Proteins and Circulating Tumor DNA Improves Risk Assessment and Subtype Stratification in Large B-Cell Lymphomas
- Author
-
Arffman, Maare, Meriranta, Leo, Jørgensen, Judit Mészáros, Holte, Harald, Fluge, Øystein, Brown, Peter de Nully, Drott, Kristina, Jyrkkiö, Sirkku, Leivonen, Suvi-Katri, and Leppä, Sirpa
- Abstract
Introduction
- Published
- 2023
- Full Text
- View/download PDF
20. Reduced Immune-Cell Infiltration in MHC Class I Negative DLBCL
- Author
-
Huse, Kanutte, Blaker, Yngvild, Wise, Jillian Frances, Sharma, Ankush, Meriranta, Leo, Isaksen, Kathrine Thuestad, Spasevska, Ivana, Nakken, Sigve, Hilden, Vera, Førsund, Mette, Leppä, Sirpa, Smeland, Erlend B., Holte, Harald, and Myklebust, June Helen
- Abstract
Background
- Published
- 2023
- Full Text
- View/download PDF
21. Clinical Impact of the Spatial Organization of the Immune Tumor Microenvironment in Diffuse Large B-Cell Lymphoma
- Author
-
Autio, Matias, Leivonen, Suvi-Katri, Karjalainen-Lindsberg, Marja-Liisa, Pellinen, Teijo, and Leppä, Sirpa
- Abstract
Introduction:Recent analyses of diffuse large B-cell lymphoma (DLBCL) have highlighted the clinical importance of immune tumor microenvironment (iTME), and based on the composition of the iTME, different DLBCL subtypes have been proposed (Kotlov et al. Cancer Discov. 2021, Steen et al. Cancer Cell. 2021). However, studies have mainly focused on the impact of different cell type proportions, whereas the clinical importance of their spatial organization has remained unclear.
- Published
- 2023
- Full Text
- View/download PDF
22. Unraveling the Transcriptional Landscape of Nodular Lymphocyte-Predominant Hodgkin Lymphoma and T-Cell/Histiocyte Rich Large B-Cell Lymphoma: Impact of Tumor Microenvironment and Checkpoint Gene Expression
- Author
-
Kalashnikov, Ilja, Russell, Veronica, Kovanen, Panu, Dunkel, Johannes, Karjalainen-Lindsberg, Marja-Liisa, Pasanen, Annika, Kositsky, Rachel, Ondrejka, Sarah L., Goyal, Tanu, Hsi, Eric D., Pedersen, Mette Ølgod, Gang, Anne Ortved, Czader, Magdalena, Zhou, Jiehao, Xu, Mina, Paulson, Nathan, Koff, Jean L., Evans, Andrew G, Natkunam, Yasodha, Juskevicius, Ridas, Louissaint, Abner, Thacker, Elizabeth, Dave, Tushar, Love, Cassandra L., McCall, Chad M, Ong, Choon Kiat, Churnetski, Michael, Martin, Haley, Chapman-Fredricks, Jennifer R., Iqbal, Javeed, Chadburn, Amy, Sojitra, Payal, Behdad, Amir, Choi, William, Xu, Jie, Mason, Emily F. Ferguson, Naresh, Kikkeri N, Fedoriw, Yuri D., Soliman, Dina Sameh, Dave, Sandeep, and Leppä, Sirpa
- Abstract
Introduction:Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare B-cell malignancy with a paucity of malignant cells embedded in a diverse tumor microenvironment (TME). The histological composition of the TME is known to influence outcomes, with nodular B-cell rich TME (classical histology, Fan patterns A&B) associated with indolent clinical course, while T-cell infiltration or diffuse growth (variant histology, Fan patterns C-F) may resemble aggressive T/cell-histiocyte rich large B-cell lymphoma (THRLBCL) to which NLPHL can transform. Molecular features of NLPHL and THRLBCL remain to be discovered. To gain further insights into the biology of these lymphomas, we recruited NLPHL and THRLBCL cases as part of the Atlas of Blood Cancer Genomes (ABCG) initiative, a consortium consisting of 26 institutions.
- Published
- 2023
- Full Text
- View/download PDF
23. Distinct Genetic and Fragmentomic Signatures of Plasma Ctdna Synergize and Resolve Clinical Challenges in Patients with Large B-Cell Lymphoma
- Author
-
Meriranta, Leo, Arffman, Maare, Jørgensen, Judit Mészáros, Holte, Harald, Drott, Kristina, Almusa, Henrikki, Saarinen, Emma, Hannula, Sari, Karjalainen-Lindsberg, Marja-Liisa, Beiske, Klaus, Pedersen, Mette Ølgod, Fluge, Øystein, Brown, Peter de Nully, Jyrkkiö, Sirkku, and Leppä, Sirpa
- Abstract
Introduction
- Published
- 2023
- Full Text
- View/download PDF
24. Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
- Author
-
Falchi, Lorenzo, Carlo-Stella, Carmelo, Morschhauser, Franck, Dickinson, Michael, Bachy, Emmanuel, Cartron, Guillaume, Khan, Cyrus, Tani, Monica, Martinez-Lopez, Joaquin, Bartlett, Nancy L., Salar, Antonio, Brody, Joshua, Leppä, Sirpa, Berthier, Aurelien, Kallemeijn, Martine, Relf, James, Chohan, Saibah, Lundberg, Linda, and Hutchings, Martin
- Abstract
Background:Glofitamab, a CD20xCD3 T-cell engaging bispecific antibody with a novel 2:1 (CD20:CD3) format, induced frequent and durable complete responses (CRs) with a manageable safety profile in pivotal expansion cohorts of an ongoing Phase I/II study (NCT03075696) in patients (pts) with R/R LBCL (Dickinson et al. NEJM 2022, Falchi et al. ASCO 2023). Cytokine release syndrome (CRS) is a potentially life-threatening toxicity caused by immune activation that can be triggered non-specifically by T-cell engaging therapies. As previously reported, corticosteroid (steroid) premedication was required to prevent or mitigate CRS in pts treated with glofitamab. Dexamethasone (Dex) was mandated in one expansion cohort to assess if this could reduce the rate and severity of CRS versus other steroids. Here, we report data from the dose-escalation and expansion cohorts in pts with R/R LBCL who received Dex only versus non-Dex premedication.
- Published
- 2023
- Full Text
- View/download PDF
25. Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial
- Author
-
Jerkeman, Mats, Kolstad, Arne, Hutchings, Martin, Pasanen, Annika, Meriranta, Leo, Niemann, Carsten Utoft, Rask Kragh Jørgensen, Rasmus, El-Galaly, Tarec Christoffer Christoffer, Riise, Jon, Leppä, Sirpa, Christensen, Jacob Haaber, Wader, Karin Fahl, and Glimelius, Ingrid
- Published
- 2022
- Full Text
- View/download PDF
26. Survival, Transformation and Causes of Death of Follicular Lymphoma: A Finnish Nationwide Population-Based Study
- Author
-
Kalashnikov, Ilja, Tanskanen, Tomas, Viisanen, Leevi, Malila, Nea, Jyrkkio, Sirkku, and Leppä, Sirpa
- Published
- 2022
- Full Text
- View/download PDF
27. Survival, Transformation and Causes of Death of Follicular Lymphoma: A Finnish Nationwide Population-Based Study
- Author
-
Kalashnikov, Ilja, Tanskanen, Tomas, Viisanen, Leevi, Malila, Nea, Jyrkkio, Sirkku, and Leppä, Sirpa
- Published
- 2022
- Full Text
- View/download PDF
28. Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial
- Author
-
Jerkeman, Mats, Kolstad, Arne, Hutchings, Martin, Pasanen, Annika, Meriranta, Leo, Niemann, Carsten Utoft, Rask Kragh Jørgensen, Rasmus, El-Galaly, Tarec Christoffer Christoffer, Riise, Jon, Leppä, Sirpa, Christensen, Jacob Haaber, Wader, Karin Fahl, and Glimelius, Ingrid
- Published
- 2022
- Full Text
- View/download PDF
29. FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders
- Author
-
Lehtonen, Jenni M., Forsström, Saara, Bottani, Emanuela, Viscomi, Carlo, Baris, Olivier R., Isoniemi, Helena, Höckerstedt, Krister, Österlund, Pia, Hurme, Mikko, Jylhävä, Juulia, Leppä, Sirpa, Markkula, Ritva, Heliö, Tiina, Mombelli, Giuliana, Uusimaa, Johanna, Laaksonen, Reijo, Laaksovirta, Hannu, Auranen, Mari, Zeviani, Massimo, Smeitink, Jan, Wiesner, Rudolf J., Nakada, Kazuto, Isohanni, Pirjo, and Suomalainen, Anu
- Published
- 2016
- Full Text
- View/download PDF
30. Blood Has Never Been Thicker: Cell-free DNA Fragmentomics in the Liquid Biopsy Toolbox of B-cell Lymphomas
- Author
-
Meriranta, Leo, Pitkänen, Esa, and Leppä, Sirpa
- Abstract
Liquid biopsies utilizing plasma circulating tumor DNA (ctDNA) are anticipated to revolutionize decision making in cancer care. In the field of lymphomas, ctDNA-based blood tests represent the forefront of clinically applicable tools to harness decades of genomic research for disease profiling, quantification and detection. More recently, the discovery of non-random fragmentation patterns in cell-free DNA (cfDNA) has opened another avenue of liquid biopsy research beyond mutational interrogation of ctDNA. Through examination of structural features, nucleotide content and genomic distribution of massive numbers of plasma cfDNA molecules, the study of fragmentomics aims at identifying new tools that augment existing ctDNA-based analyses and discover new ways to profile cancer from blood tests. Indeed, the characterization of aberrant lymphoma ctDNA fragment patterns and harnessing them with powerful machine learning techniques are expected to unleash the potential of non-mutant molecules for liquid biopsy purposes. In this article, we review cfDNA fragmentomics as an emerging approach in the ctDNA research of B-cell lymphomas. We summarize the biology behind formation of cfDNA fragment patterns and discuss the preanalytical and technical limitations faced with current methodologies. Then we go through the advances in the field of lymphomas and envision what other non-invasive tools based on fragment characteristics could be explored. Last, we place fragmentomics as one of the facets of ctDNA analyses in emerging multi-view and multi-omics liquid biopsies. We pay attention to the unknowns in the field of cfDNA fragmentation biology that warrant further mechanistic investigation to provide rational background for the development of these precision oncology tools and understanding of their limitations.
- Published
- 2023
- Full Text
- View/download PDF
31. Prognostic impact of protein kinase C β II expression in R-CHOP-treated diffuse large B-cell lymphoma patients
- Author
-
Riihijärvi, Sari, Koivula, Satu, Nyman, Heidi, Rydström, Karin, Jerkeman, Mats, and Leppä, Sirpa
- Abstract
Development of targeted agents for the treatment of diffuse large B-cell lymphoma includes clinical evaluation of enzastaurin, an agent that suppresses signaling through protein kinase C-βand AKT pathways. To determine whether protein kinase C-βexpression has prognostic significance for diffuse large B-cell lymphoma patients treated with immunochemotherapy, we analyzed the expression of protein kinase C-βII, BCL-2 and cell of origin immunohistochemically from pretreatment samples of 95 diffuse large B-cell lymphoma patients. All patients received rituximab with CHOP or CHOEP. According to Kaplan–Meier analyses, overall survival at 3 years was better among the patients with low than high protein kinase C-βII protein levels (94 vs76%, P=0.036). The prognostic value of protein kinase C-βII expression on survival was seen in the patients with low and high International Prognostic Index risk groups, and in all molecular entities. Gene expression data from an independent set of 233 diffuse large B-cell lymphoma patients treated with a combination of rituximab and CHOP-like chemotherapy was analyzed in comparison. Accordingly, a better 3-year overall survival was observed among the subgroup with low protein kinase C-βII mRNA levels (84 vs68%, P=0.005). In multivariate analysis with cell of origin, protein kinase C-βII mRNA expression remained as an independent predictor for overall survival. Together, the data show that protein kinase C-βII expression has prognostic significance in diffuse large B-cell lymphoma patients treated with immunochemotherapy.
- Published
- 2010
- Full Text
- View/download PDF
32. Prognostic impact of protein kinase C β II expression in R-CHOP-treated diffuse large B-cell lymphoma patients
- Author
-
Riihijärvi, Sari, Koivula, Satu, Nyman, Heidi, Rydström, Karin, Jerkeman, Mats, and Leppä, Sirpa
- Abstract
Development of targeted agents for the treatment of diffuse large B-cell lymphoma includes clinical evaluation of enzastaurin, an agent that suppresses signaling through protein kinase C-β and AKT pathways. To determine whether protein kinase C-β expression has prognostic significance for diffuse large B-cell lymphoma patients treated with immunochemotherapy, we analyzed the expression of protein kinase C-β II, BCL-2 and cell of origin immunohistochemically from pretreatment samples of 95 diffuse large B-cell lymphoma patients. All patients received rituximab with CHOP or CHOEP. According to Kaplan–Meier analyses, overall survival at 3 years was better among the patients with low than high protein kinase C-β II protein levels (94 vs 76%, P=0.036). The prognostic value of protein kinase C-β II expression on survival was seen in the patients with low and high International Prognostic Index risk groups, and in all molecular entities. Gene expression data from an independent set of 233 diffuse large B-cell lymphoma patients treated with a combination of rituximab and CHOP-like chemotherapy was analyzed in comparison. Accordingly, a better 3-year overall survival was observed among the subgroup with low protein kinase C-β II mRNA levels (84 vs 68%, P=0.005). In multivariate analysis with cell of origin, protein kinase C-β II mRNA expression remained as an independent predictor for overall survival. Together, the data show that protein kinase C-β II expression has prognostic significance in diffuse large B-cell lymphoma patients treated with immunochemotherapy.
- Published
- 2010
- Full Text
- View/download PDF
33. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
- Author
-
Nyman, Heidi, Jerkeman, Mats, Karjalainen-Lindsberg, Marja-Liisa, Banham, Alison H, and Leppä, Sirpa
- Abstract
Gene expression profiling studies initially enabled diffuse large B-cell lymphoma to be divided into germinal center and activated B-cell-like subtypes, which define high- and low-risk patient groups when treated with chemotherapy. Attempts to reproduce the prognostic classification immunohistochemically have, however, provided inconsistent results. The aim of this study was to determine whether modified immunohistochemical classification of cell of origin focusing on activated B-cell-like markers could be used to predict the outcome of immunochemotherapy-treated diffuse large B-cell lymphoma patients. The expression of CD10, Bcl-6, MUM1/IRF4, Bcl-2, and FOXP1 was determined immunohistochemically from 88 samples of diffuse large B-cell lymphoma patients treated uniformly with R-CHOP. When the modified classification using MUM1/IRF4 and FOXP1 positivities as activated B-cell-like markers was applied to distinguish the patients between the activated B-cell-like and other diffuse large B-cell lymphoma subtypes, a significantly worse outcome was seen for the patients with the activated B-cell-like phenotype (3-year failure-free survival 63 vs82%, P=0.048, overall survival 69 vs85%, P=0.110). Similarly, according to the Muris algorithm, the group 2 patients representing Bcl-2-positive post-germinal center patients showed an inferior outcome in comparison to the group 1 patients (failure-free survival 59 vs81%, P=0.041, overall survival 67 vs82%, P=0.159). In contrast, when the classification of the same cohort was performed according to the Hans algorithm, no significant difference in survival was observed between the germinal center and non-germinal center patients. In conclusion, the data suggest that both the modified activated B-cell-like and Muris classifications define the non-germinal center phenotype as an adverse risk factor in R-CHOP-treated diffuse large B-cell lymphoma patients.
- Published
- 2009
- Full Text
- View/download PDF
34. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
- Author
-
Nyman, Heidi, Jerkeman, Mats, Karjalainen-Lindsberg, Marja-Liisa, Banham, Alison H, and Leppä, Sirpa
- Abstract
Gene expression profiling studies initially enabled diffuse large B-cell lymphoma to be divided into germinal center and activated B-cell-like subtypes, which define high- and low-risk patient groups when treated with chemotherapy. Attempts to reproduce the prognostic classification immunohistochemically have, however, provided inconsistent results. The aim of this study was to determine whether modified immunohistochemical classification of cell of origin focusing on activated B-cell-like markers could be used to predict the outcome of immunochemotherapy-treated diffuse large B-cell lymphoma patients. The expression of CD10, Bcl-6, MUM1/IRF4, Bcl-2, and FOXP1 was determined immunohistochemically from 88 samples of diffuse large B-cell lymphoma patients treated uniformly with R-CHOP. When the modified classification using MUM1/IRF4 and FOXP1 positivities as activated B-cell-like markers was applied to distinguish the patients between the activated B-cell-like and other diffuse large B-cell lymphoma subtypes, a significantly worse outcome was seen for the patients with the activated B-cell-like phenotype (3-year failure-free survival 63 vs 82%, P=0.048, overall survival 69 vs 85%, P=0.110). Similarly, according to the Muris algorithm, the group 2 patients representing Bcl-2-positive post-germinal center patients showed an inferior outcome in comparison to the group 1 patients (failure-free survival 59 vs 81%, P=0.041, overall survival 67 vs 82%, P=0.159). In contrast, when the classification of the same cohort was performed according to the Hans algorithm, no significant difference in survival was observed between the germinal center and non-germinal center patients. In conclusion, the data suggest that both the modified activated B-cell-like and Muris classifications define the non-germinal center phenotype as an adverse risk factor in R-CHOP-treated diffuse large B-cell lymphoma patients.Modern Pathology (2009) 22, 1094–1101; doi:10.1038/modpathol.2009.73; published online 15 May 2009
- Published
- 2009
- Full Text
- View/download PDF
35. Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)
- Author
-
Dickinson, Michael, Carlo-Stella, Carmelo, Morschhauser, Franck, Patel, Krish, Khan, Cyrus, Bartlett, Nancy L., Iacoboni, Gloria, Hertzberg, Mark, Leppä, Sirpa, Van Den Neste, Eric, Tani, Monica, Cartron, Guillaume, Salar, Antonio, Perez-Callejo, David, Lundberg, Linda, Relf, James, Clark, Emma, Humphrey, Kathryn, and Hutchings, Martin
- Published
- 2021
- Full Text
- View/download PDF
36. Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)
- Author
-
Dickinson, Michael, Carlo-Stella, Carmelo, Morschhauser, Franck, Patel, Krish, Khan, Cyrus, Bartlett, Nancy L., Iacoboni, Gloria, Hertzberg, Mark, Leppä, Sirpa, Van Den Neste, Eric, Tani, Monica, Cartron, Guillaume, Salar, Antonio, Perez-Callejo, David, Lundberg, Linda, Relf, James, Clark, Emma, Humphrey, Kathryn, and Hutchings, Martin
- Abstract
Dickinson: Amgen: Honoraria; Celgene: Research Funding; Takeda: Research Funding; Gilead Sciences: Consultancy, Honoraria, Speakers Bureau; MSD: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Other: travel, accommodation, expenses, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Research Funding, Speakers Bureau. Carlo-Stella: Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen Oncology: Honoraria; Celgene: Membership on an entity's Board of Directors or advisory committees; Karyopharm Therapeutics: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Honoraria; Incyte: Honoraria; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Research Funding. Morschhauser: Epizyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Chugai: Honoraria; Incyte: Membership on an entity's Board of Directors or advisory committees; Servier: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Speakers Bureau; Genentech, Inc.: Consultancy; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genmab: Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; AstraZenenca: Membership on an entity's Board of Directors or advisory committees. Patel: BeiGene: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Celgene: Consultancy, Research Funding, Speakers Bureau; Fate Therapeutics: Research Funding; Genentech/Roche: Consultancy, Research Funding, Speakers Bureau; Juno Pharmaceuticals: Consultancy; Kite: Consultancy, Research Funding, Speakers Bureau; MEI Pharma: Consultancy, Research Funding; TG Therapeutics: Consultancy, Speakers Bureau; Trillium Therapeutics: Research Funding; Sunesis Pharmaceuticals: Research Funding; Pharmacyclics/Janssen: Consultancy, Research Funding, Speakers Bureau; Morphosys: Consultancy; Xencor: Research Funding; Curis, Inc: Research Funding; Abbvie: Consultancy; Millenium/Takeda: Research Funding; Velos Bio: Research Funding; Aptevo Therapeutics: Research Funding; AstraZeneca: Consultancy, Research Funding, Speakers Bureau. Khan: Genentech: Research Funding, Speakers Bureau; Astrazeneca: Research Funding, Speakers Bureau; Epizyme: Research Funding, Speakers Bureau; Beigene: Research Funding, Speakers Bureau; Abbvie: Research Funding, Speakers Bureau; Sanofi: Speakers Bureau; Karyopharm: Speakers Bureau; SeaGen: Speakers Bureau; Morphosys: Speakers Bureau; Kite: Speakers Bureau; GSK: Speakers Bureau. Bartlett: Affimed: Research Funding; Autolus: Research Funding; Bristol-Myers Squibb: Research Funding; Celgene: Research Funding; Forty Seven: Research Funding; Janssen: Research Funding; Kite Pharma: Research Funding; Merck: Research Funding; Millennium: Research Funding; Pharmacyclics: Research Funding; Genentech, Inc./F. Hoffmann-La Roche Ltd: Membership on an entity's Board of Directors or advisory committees, Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Washington University School of Medicine: Current Employment. Iacoboni: BMS/Celgene, Gilead, Novartis, Janssen, Roche: Honoraria. Hertzberg: Roche: Honoraria, Speakers Bureau; MSD: Honoraria; BMS: Honoraria; Takeda: Honoraria; Gilead: Honoraria. Leppä: Genmab: Research Funding; Orion: Consultancy; CHO Pharma USA: Consultancy; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; MSD: Membership on an entity's Board of Directors or advisory committees; University of Helsinki and Helsinki University Hospital: Current Employment; Takeda: Research Funding; Bayer: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding. Van Den Neste: Novartis: Consultancy, Research Funding; Roche: Research Funding; Celgene: Consultancy. Cartron: Roche, Celgene-BMS: Consultancy; Danofi, Gilead, Novartis, Jansen, Roche, Celgene-BMS, Abbvie, Takeda: Honoraria. Salar: Beigene: Consultancy; BMS/Celgene: Consultancy, Speakers Bureau; EusaPharma: Consultancy; Janssen: Consultancy, Speakers Bureau; Hospital del Mar: Current Employment; Abbvie: Research Funding. Perez-Callejo: F. Hoffmann-La Roche Ltd: Current Employment, Current equity holder in publicly-traded company. Lundberg: F. Hoffmann-La Roche Ltd: Current Employment, Current equity holder in publicly-traded company. Relf: F-Star Therapeutics: Current equity holder in publicly-traded company, Divested equity in a private or publicly-traded company in the past 24 months; Harpoon Therapeutics: Divested equity in a private or publicly-traded company in the past 24 months; Roche Pharmaceutical Ltd: Current Employment, Current equity holder in publicly-traded company. Clark: Roche Products Ltd: Current Employment. Humphrey: Roche: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Hutchings: Novartis: Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding; Incyte: Research Funding; Janssen: Honoraria, Research Funding; Genmab: Consultancy, Honoraria, Research Funding; Celgene: Research Funding; Genentech: Honoraria, Research Funding.Glofitamab is a full-length, humanized immunoglobulin G1 bispecific antibodywith a 2:1 molecular format that facilitates bivalent binding to CD20 on B-cells, and monovalent binding to CD3 on T-cells. Glofitamab redirects T cells to engage and eliminate malignant B cells. Glofitamab is an investigational agent.
- Published
- 2021
- Full Text
- View/download PDF
37. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP
- Author
-
Taskinen, Minna, Karjalainen-Lindsberg, Marja-Liisa, and Leppä, Sirpa
- Abstract
Gene expression profiling and immunohistochemical studies have demonstrated that nonmalignant tumor infiltrating inflammatory cells contribute to clinical outcome in patients with follicular lymphoma (FL). Particularly, tumor-associated macrophage (TAM) content correlates with longer survival rates after immunochemotherapy. Here we investigated the prognostic importance of tumor-associated mast cells (MCs) and their relation to TAMs in patients with FL treated with a combination of rituximab (R) and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. Of the 98 patients, 70 received R-CHOP at diagnosis and 28 at relapse. According to Kaplan-Meier estimates, the patients with high MC content had a worse 4-year progression-free survival (PFS) than the ones with low MC content after R-CHOP therapy (34% vs 74%, P = .002). The adverse prognostic value of MCs was seen both for the patients treated at diagnosis and at relapse, whereas no such impact on PFS was observed for the control patients treated with chemotherapy only (P = .4). When the TAM-related PFS was analyzed separately in patients with high and low MC contents, the positive prognostic effect of TAM was seen only in patients with few MCs. Taken together, the data demonstrate that a high MC score is associated with unfavorable prognosis and it eliminates the positive prognostic value of TAMs in patients with FL treated with immunochemotherapy.
- Published
- 2008
- Full Text
- View/download PDF
38. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP
- Author
-
Taskinen, Minna, Karjalainen-Lindsberg, Marja-Liisa, and Leppä, Sirpa
- Abstract
Gene expression profiling and immunohistochemical studies have demonstrated that nonmalignant tumor infiltrating inflammatory cells contribute to clinical outcome in patients with follicular lymphoma (FL). Particularly, tumor-associated macrophage (TAM) content correlates with longer survival rates after immunochemotherapy. Here we investigated the prognostic importance of tumor-associated mast cells (MCs) and their relation to TAMs in patients with FL treated with a combination of rituximab (R) and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. Of the 98 patients, 70 received R-CHOP at diagnosis and 28 at relapse. According to Kaplan-Meier estimates, the patients with high MC content had a worse 4-year progression-free survival (PFS) than the ones with low MC content after R-CHOP therapy (34% vs 74%, P= .002). The adverse prognostic value of MCs was seen both for the patients treated at diagnosis and at relapse, whereas no such impact on PFS was observed for the control patients treated with chemotherapy only (P= .4). When the TAM-related PFS was analyzed separately in patients with high and low MC contents, the positive prognostic effect of TAM was seen only in patients with few MCs. Taken together, the data demonstrate that a high MC score is associated with unfavorable prognosis and it eliminates the positive prognostic value of TAMs in patients with FL treated with immunochemotherapy.
- Published
- 2008
- Full Text
- View/download PDF
39. Hydrocortisone and Indomethacin Negatively Modulate EGF-R Signaling in Human Fetal Intestine
- Author
-
KAJANNE, RISTO, LEPPÄ, SIRPA, LUUKKAINEN, PÄIVI, USTINOV, JARKKO, THIEL, ALEXANDRA, RISTIMÄKI, ARI, and MIETTINEN, PÄIVI J.
- Abstract
Concomitant use of hydrocortisone and the nonspecific cyclo-oxygenase (COX)-inhibitor indomethacin increases the risk for intestinal perforations in preterm infants. We determined whether this was associated with insufficient epidermal growth factor receptor (EGF-R) signaling. We tested the effect of EGF, hydrocortisone, and indomethacin on its activation, cell proliferation and migration, COX-2 expression, and prostaglandin E2(PGE2) production. Human small intestine epithelial cell line FHsInt74 and EGF-R–deficient mice EGF-R (–/–) were used as models. The data revealed that EGF-R signaling had a bimodal positive effect on fetal enterocyte: 1) it increased cell proliferation and migration synergistically with hydrocortisone and 2) up-regulated COX-2 mRNA expression and subsequent PGE2production. Correlating with this, COX-2 protein expression was down-regulated in EGF-R (–/–) intestine. Despite a positive effect on cell proliferation with EGF, hydrocortisone blunted the stimulatory effect of EGF on COX-2 expression and PGE2production. Addition of indomethacin even further inhibited the EGF-stimulated PGE2synthesis. The data suggest that concomitant use of indomethacin and hydrocortisone on preterm infants, who physiologically synthesize only low levels of EGF-R ligands, may lead to intestinal problems related to failure in cytoprotective and regenerative events.
- Published
- 2007
- Full Text
- View/download PDF
40. Hydrocortisone and Indomethacin Negatively Modulate EGF-R Signaling in Human Fetal Intestine
- Author
-
Kajanne, Risto, Leppä, Sirpa, Luukkainen, Päivi, Ustinov, Jarkko, Thiel, Alexandra, Ristimäki, Ari, and Miettinen, Päivi J
- Abstract
Concomitant use of hydrocortisone and the nonspecific cyclo-oxygenase (COX)-inhibitor indomethacin increases the risk for intestinal perforations in preterm infants. We determined whether this was associated with insufficient epidermal growth factor receptor (EGF-R) signaling. We tested the effect of EGF, hydrocortisone, and indomethacin on its activation, cell proliferation and migration, COX-2 expression, and prostaglandin E2(PGE2) production. Human small intestine epithelial cell line FHsInt74 and EGF-R–deficient mice [EGF-R (–/–)] were used as models. The data revealed that EGF-R signaling had a bimodal positive effect on fetal enterocyte: 1) it increased cell proliferation and migration synergistically with hydrocortisone and 2) up-regulated COX-2 mRNA expression and subsequent PGE2production. Correlating with this, COX-2 protein expression was down-regulated in EGF-R (–/–) intestine. Despite a positive effect on cell proliferation with EGF, hydrocortisone blunted the stimulatory effect of EGF on COX-2 expression and PGE2production. Addition of indomethacin even further inhibited the EGF-stimulated PGE2synthesis. The data suggest that concomitant use of indomethacin and hydrocortisone on preterm infants, who physiologically synthesize only low levels of EGF-R ligands, may lead to intestinal problems related to failure in cytoprotective and regenerative events.
- Published
- 2007
- Full Text
- View/download PDF
41. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy
- Author
-
Nyman, Heidi, Adde, Magdalena, Karjalainen-Lindsberg, Marja-Liisa, Taskinen, Minna, Berglund, Mattias, Amini, Rose-Marie, Blomqvist, Carl, Enblad, Gunilla, and Leppä, Sirpa
- Abstract
Germinal center (GC) and non-GC phenotypes are predictors of outcome in diffuse large B-cell lymphoma (DLBCL) and can be used to stratify chemotherapy-treated patients into low- and high-risk groups. To determine how combination of rituximab with chemotherapy influences GC-associated clinical outcome, GC and non-GC phenotypes were identified immunohistochemically from samples of 90 de novo DLBCL patients treated with rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)–like regimen (immunochemotherapy). One hundred and four patients previously treated with chemotherapy served as a control group. Consistent with previous studies, chemotherapy-treated patients with immunohistochemically defined GC phenotype displayed a significantly better overall (OS) and failure-free survival (FFS) than the non-GC group (OS, 70% vs 47%, P= .012; FFS, 59% vs 30%, P= .001). In contrast, immunohistochemically defined GC phenotype did not predict outcome in immunochemotherapy-treated patients (OS, 77% vs 76%, P= ns; FFS, 68% vs 63%, P= ns). In comparison, International Prognostic Index (IPI) could separate the high-risk patients from low- and intermediate-risk groups (OS, 84% vs 63%, P= .030; FFS, 79% vs 52%, P= .028). We conclude that rituximab in combination with chemotherapy seems to eliminate the prognostic value of immunohistochemically defined GC- and non-GC phenotypes in DLBCL.
- Published
- 2007
- Full Text
- View/download PDF
42. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy
- Author
-
Nyman, Heidi, Adde, Magdalena, Karjalainen-Lindsberg, Marja-Liisa, Taskinen, Minna, Berglund, Mattias, Amini, Rose-Marie, Blomqvist, Carl, Enblad, Gunilla, and Leppä, Sirpa
- Abstract
Germinal center (GC) and non-GC phenotypes are predictors of outcome in diffuse large B-cell lymphoma (DLBCL) and can be used to stratify chemotherapy-treated patients into low- and high-risk groups. To determine how combination of rituximab with chemotherapy influences GC-associated clinical outcome, GC and non-GC phenotypes were identified immunohistochemically from samples of 90 de novo DLBCL patients treated with rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)–like regimen (immunochemotherapy). One hundred and four patients previously treated with chemotherapy served as a control group. Consistent with previous studies, chemotherapy-treated patients with immunohistochemically defined GC phenotype displayed a significantly better overall (OS) and failure-free survival (FFS) than the non-GC group (OS, 70% vs 47%, P = .012; FFS, 59% vs 30%, P = .001). In contrast, immunohistochemically defined GC phenotype did not predict outcome in immunochemotherapy-treated patients (OS, 77% vs 76%, P = ns; FFS, 68% vs 63%, P = ns). In comparison, International Prognostic Index (IPI) could separate the high-risk patients from low- and intermediate-risk groups (OS, 84% vs 63%, P = .030; FFS, 79% vs 52%, P = .028). We conclude that rituximab in combination with chemotherapy seems to eliminate the prognostic value of immunohistochemically defined GC- and non-GC phenotypes in DLBCL.
- Published
- 2007
- Full Text
- View/download PDF
43. Mitogen-activated Protein Kinases and Activator Protein 1 Are Required for Proliferation and Cardiomyocyte Differentiation of P19 Embryonal Carcinoma Cells*
- Author
-
Eriksson, Minna and Leppä, Sirpa
- Abstract
Mitogen-activated protein kinases (MAPKs) have been implicated as regulators of differentiation. The biological effect of MAPK signaling in the nucleus is achieved by signal-responsive transcription factors. Here we have investigated MAPK signaling and activation of AP-1 transcription factors in P19 embryonal carcinoma cells undergoing cardiomyocyte differentiation. We show that aggregation and Me2SO treatment, which trigger the differentiation response, result in sustained activation of JNK1, p38, and ERK1/2 MAPKs and acquisition of AP-1 DNA binding activity. The induced AP-1 activity consists of c-Jun, JunD, and Fra-2 proteins and is accompanied with the increased expression of these proteins. JNK is involved in c-Jun phoshorylation, whereas ERK and p38 activities are essential for maximal c-Jun and Fra-2 expression, and AP-1 DNA binding activity. While the inhibition of ERK can partially prevent the formation of beating cardiomyocytes, the activity of p38 is absolutely required for the differentiation. Expression of dominant negative c-JunbZIPin P19 cells can also inhibit the differentiation response. Surprisingly, however, expression of dominant negative SEK or JNK causes an inhibition of P19 cell proliferation. Taken together, the results show that ERK, JNK, p38, and AP-1 are activated in a coordinated and sustained manner, and contribute to proliferation and cardiomyocyte differentiation of P19 cells.
- Published
- 2002
- Full Text
- View/download PDF
44. Complex Functions of AP-1 Transcription Factors in Differentiation and Survival of PC12 Cells
- Author
-
Leppä, Sirpa, Eriksson, Minna, Saffrich, Rainer, Ansorge, Wilhelm, and Bohmann, Dirk
- Abstract
c-Jun activation by mitogen-activated protein kinases has been implicated in various cellular signal responses. We investigated how JNK and c-Jun contribute to neuronal differentiation, cell survival, and apoptosis. In differentiated PC12 cells, JNK signaling can induce apoptosis and c-Jun mediates this response. In contrast, we show that in PC12 cells that are not yet differentiated, the AP-1 family member ATF-2 and not c-Jun acts as an executor of apoptosis. In this context c-Jun expression protects against apoptosis and triggers neurite formation. Thus, c-Jun has opposite functions before and after neuronal differentiation. These findings suggest a model in which the balance between ATF-2 and Jun activity in PC12 cells governs the choice between differentiation towards a neuronal fate and an apoptotic program. Further analysis of c-Jun mutants showed that the differentiation response requires functional dimerization and DNA-binding domains and that it is stimulated by phosphorylation in the transactivation domain. In contrast, c-Jun mutants incompetent for DNA binding or dimerization and also mutants lacking JNK binding and phosphorylation sites that cannot elicit neuronal differentiation efficiently protect PC12 cells from apoptosis. Hence, the protective role of c-Jun appears to be mediated by an unconventional mechanism that is separable from its function as a classical AP-1 transcription factor.
- Published
- 2001
- Full Text
- View/download PDF
45. Complex Functions of AP-1 Transcription Factors in Differentiation and Survival of PC12 Cells
- Author
-
Leppä, Sirpa, Eriksson, Minna, Saffrich, Rainer, Ansorge, Wilhelm, and Bohmann, Dirk
- Abstract
ABSTRACTc-Jun activation by mitogen-activated protein kinases has been implicated in various cellular signal responses. We investigated how JNK and c-Jun contribute to neuronal differentiation, cell survival, and apoptosis. In differentiated PC12 cells, JNK signaling can induce apoptosis and c-Jun mediates this response. In contrast, we show that in PC12 cells that are not yet differentiated, the AP-1 family member ATF-2 and not c-Jun acts as an executor of apoptosis. In this context c-Jun expression protects against apoptosis and triggers neurite formation. Thus, c-Jun has opposite functions before and after neuronal differentiation. These findings suggest a model in which the balance between ATF-2 and Jun activity in PC12 cells governs the choice between differentiation towards a neuronal fate and an apoptotic program. Further analysis of c-Jun mutants showed that the differentiation response requires functional dimerization and DNA-binding domains and that it is stimulated by phosphorylation in the transactivation domain. In contrast, c-Jun mutants incompetent for DNA binding or dimerization and also mutants lacking JNK binding and phosphorylation sites that cannot elicit neuronal differentiation efficiently protect PC12 cells from apoptosis. Hence, the protective role of c-Jun appears to be mediated by an unconventional mechanism that is separable from its function as a classical AP-1 transcription factor.
- Published
- 2001
- Full Text
- View/download PDF
46. Stage-Specific Expression and Cellular Localization of the Heat Shock Factor 2 Isoforms in the Rat Seminiferous Epithelium
- Author
-
Alastalo, Tero-Pekka, Lönnström, Minna, Leppä, Sirpa, Kaarniranta, Kai, Pelto-Huikko, Markku, Sistonen, Lea, and Parvinen, Martti
- Abstract
Heat shock transcription factors (HSFs) are generally known as regulators of cellular stress response. The mammalian HSF1 functions as a classical stress factor, whereas HSF2 is active during certain developmental processes, including embryogenesis and spermatogenesis. In the present study, we examined HSF2 expression at specific stages of the rat seminiferous epithelial cycle. We found that expression of the alternatively spliced HSF2-α and HSF2-β isoforms is developmentally regulated in a stage-specific manner. Studies on cellular localization demonstrated that HSF2 is present in the nuclei of early pachytene spermatocytes at stages I–IV and in the nuclei of round spermatids at stages V–VIIab. In contrast a strong HSF2 immunoreactivity was detected in small distinct cytoplasmic regions from zygotene spermatocytes to maturation phase spermatids. Immunoelectron microscopic analysis revealed that these structures are mainly cytoplasmic bridges between germ cells. Our results on cellular localization of HSF2 and stage-specific expression of the HSF2 isoforms indicate that HSF2, in addition to its function as a nuclear transcription factor, may be involved in other cellular processes during spermatogenesis, possibly in the sharing process of gene products between the germ cells.
- Published
- 1998
- Full Text
- View/download PDF
47. Syndecan-1 expression in mammary epithelial tumor cells is E-cadherin-dependent
- Author
-
Leppä, Sirpa, Vleminckx, Kris, Roy, Frans Van, and Jalkanen, Markku
- Abstract
E-cadherin is a Ca2+-dependent cell-cell adhesion molecule, which is mainly expressed in epithelial cells. Recent studies have shown that E-cadherin has an important role as an invasion suppressor molecule in epithelial tumor cells. Syndecan-1 is a cell surface proteoglycan that has been implicated in a number of cellular functions including cell-cell adhesion, cell-matrix anchorage and growth factor pre-sentation for signalling receptors. Its suppression has also been shown to be associated with malignant transforma-tion of epithelial cells. In order to better understand the coordinated regulation of cell-cell and cell-matrix interac-tions during malignant transformation, we have studied the expression of syndecan-1 in malignant mammary tumor cells genetically manipulated for E-cadherin expression. In invasive NM-e-ras-MAC1 cells, where E-cadherin was partially downregulated by specific antisense RNA, syndecan-1 expression was suppressed. Furthermore, transfection of E-cadherin cDNA into invasive NM-f-ras-TD cells resulted in the upregulation of syndecan-1 expression in association with decreased invasiveness. In both cases, regulation of syndecan-1 occurred post-tran-scriptionally, since syndecan-1 mRNA levels remained unchanged. Instead, a translational regulation is suggested, since syndecan-1 core protein synthesis was E-cadherin dependent. Another cell adhesion protein, β1-integrin was not affected by E-cadherin expression. The data provide an example of coordinated changes in the expression of two cell adhesion molecules, syndecan-1 and E-cadherin during epithelial cell transformation.
- Published
- 1996
- Full Text
- View/download PDF
48. The Phorbol Ester 12-O-Tetradecanoylphorbol 13-Acetate Enhances the Heat-induced Stress Response*
- Author
-
Holmberg, Carina I., Leppä, Sirpa, Eriksson, John E., and Sistonen, Lea
- Abstract
Induction of heat shock gene expression is mediated by specific heat shock transcription factors (HSFs), but the signaling pathways leading to activation of HSFs are poorly understood. To elucidate whether protein kinase C-responsive signaling pathways could be involved in the regulation of heat shock gene expression, we have examined the effects of the protein kinase C activator 12-O-tetradecanoylphorbol 13-acetate (TPA) on the heat-induced stress response in K562 cells. We demonstrate that TPA treatment markedly enhances heat shock gene expression during heat stress, although TPA alone does not induce the heat shock response. This TPA-mediated enhancement can initially be detected as an accelerated acquisition of DNA binding and transcriptional activity of HSF1 resulting in elevated Hsp70 protein concentrations. In the presence of TPA, the attenuation of HSF1 DNA binding activity during continuous exposure to heat shock occurs more rapidly and in concert with the appearance of newly synthesized Hsp70, which supports earlier studies on the autoregulatory role of Hsp70 in deactivation of HSF1. During heat stress, a correlation between the hyperphosphorylation of HSF1 and its transcriptional activity was observed, in both the presence and the absence of TPA. Our results show that the heat-induced stress response can be significantly modulated by activation of protein kinase C-responsive signaling pathways.
- Published
- 1997
- Full Text
- View/download PDF
49. Overexpression of HSF2-β Inhibits Hemin-induced Heat Shock Gene Expression and Erythroid Differentiation in K562 Cells*
- Author
-
Leppä, Sirpa, Pirkkala, Lila, Saarento, Helena, Sarge, Kevin D., and Sistonen, Lea
- Abstract
Acquisition of heat shock factor 2 (HSF2) DNA binding activity is accompanied by induced transcription of heat shock genes in hemin-treated K562 cells undergoing erythroid differentiation. Previous studies revealed that HSF2 consists of two alternatively spliced isoforms, HSF2-α and HSF2-β, whose relative abundance is developmentally regulated and varies between different tissues. To investigate whether the molar ratio of HSF2-α and HSF2-β isoforms is crucial for the activation of HSF2 and whether the HSF2 isoforms play functionally distinct roles during the hemin-mediated erythroid differentiation, we generated cell clones expressing different levels of HSF2-α and HSF2-β. We show that in parental K562 cells, the HSF2-α isoform is predominantly expressed and HSF2 can be activated upon hemin treatment. In contrast, when HSF2-β is expressed at levels exceeding those of endogenous HSF2-α, the hemin-induced DNA binding activity and transcription of heat shock genes are repressed, whereas overexpression of HSF2-α results in an enhanced hemin response. Furthermore, the hemin-induced accumulation of globin, known as a marker of erythroid differentiation, is decreased in cells overexpressing HSF2-β. We suggest that HSF2-β acts as a negative regulator of HSF2 activity during hemin-mediated erythroid differentiation of K562 cells.
- Published
- 1997
- Full Text
- View/download PDF
50. Syndecan, a regulator of cell behaviour, is lost in malignant transformation
- Author
-
Jalkanen, Markku, Elenius, Klaus, Inki, Pirjo, Kirjavainen, Jarkko, and Leppä, Sirpa
- Published
- 1991
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.